References
- Anagnostis P, Bitzer J, Cano A, et al. Menopause symptom management in women with dyslipidemias: an EMAS clinical guide. Maturitas. 2020;135:82–88. doi: 10.1016/j.maturitas.2020.03.007.
- Zhang GQ, Chen JL, Luo Y, et al. Menopausal hormone therapy and women’s health: an umbrella review. PLoS Med. 2021;18(8):e1003731. doi: 10.1371/journal.pmed.1003731.
- Verdonk P, Bendien E, Appelman Y. Menopause and work: a narrative literature review about menopause, work and health. Work. 2022;72(2):483–496. doi: 10.3233/WOR-205214.
- Hogervorst E, Craig J, O’Donnell E. Cognition and mental health in menopause: a review. Best Pract Res Clin Obstet Gynaecol. 2022;81:69–84. doi: 10.1016/j.bpobgyn.2021.10.009.
- National Institute for Health and Care Excellence. 2019 Surveillance of menopause: diagnosis and management. London: National Institute for Health and Care Excellence (NICE); 2019.
- The Lancet Diabetes & Endocrinology. Menopause: a turning point for women’s health. Lancet Diabetes Endocrinol. 2022;10(6):373. Available from: http://www.thelancet.com/article/S2213858722001425/fulltext
- The British Menopause Society. Risk of suboptimal hormone replacement therapy for young hypogonadal women and transgender women in the wake of the Joint BMS FSRH RCGP RCOG SfE and RCN Women’s Health Forum safety alert. Clin Endocrinol (Oxf). 2023;99(3):326–327.
- Menopause [Internet]. [cited 2023 May 8]. Available from: https://www.who.int/news-room/fact-sheets/detail/menopause.
- Cagnacci A, Venier M. The controversial history of hormone replacement therapy. Medicina (B Aires). 2019;55(9):602.
- Hickey M, Hunter MS, Santoro N, et al. Normalising menopause. BMJ. 2022;377:e069369. Available from: https://www.bmj.com/content/377/bmj-2021-069369
- Guo PP, Li P, Zhang XH, et al. Complementary and alternative medicine for natural and treatment-induced vasomotor symptoms: an overview of systematic reviews and meta-analyses. Complement Ther Clin Pract. 2019;36:181–194. doi: 10.1016/j.ctcp.2019.07.007.
- Jack G, Riach K, Bariola E, et al. Menopause in the workplace: what employers should be doing. Maturitas. 2016;85:88–95. doi: 10.1016/j.maturitas.2015.12.006.
- Temkin SM, Mallen A, Bellavance E, et al. The role of menopausal hormone therapy in women with or at risk of ovarian and breast cancers: misconceptions and current directions. Cancer. 2019;125(4):499–514. Available from: doi: 10.1002/cncr.31911.
- Weiss R. Menopause and social media: pros and cons for the general public. Maturitas. 2023;174:67–68. http://www.maturitas.org/article/S0378512223000373/fulltext
- Furness S, Roberts H, Marjoribanks J, et al. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev. 2012;2012(8):CD000402. Available from: doi: 10.1002/14651858.CD000402.pub4/full.
- Sare GM, Gray LJ, Bath PMW. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J. 2008;29(16):2031–2041. Available from: https://academic.oup.com/eurheartj/article/29/16/2031/409204 doi: 10.1093/eurheartj/ehn299.
- Marjoribanks J, Farquhar C, Roberts H, et al. Long‐term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2017;1(1):CD004143. doi: 10.1002/14651858.CD004143.pub5.
- Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701–1712. Available from: https://pubmed.ncbi.nlm.nih.gov/15082697/
- Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333. Available from: https://pubmed.ncbi.nlm.nih.gov/12117397/
- Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280(7):605–613. Available from: https://pubmed.ncbi.nlm.nih.gov/9718051/ doi: 10.1001/jama.280.7.605.
- Vickers MR, MacLennan AH, Lawton B, et al. Main morbidities recorded in the women’s international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ. 2007;335(7613):239–244. Available from: https://pubmed.ncbi.nlm.nih.gov/17626056/ doi: 10.1136/bmj.39266.425069.AD.
- Stevenson JC, Hodis HN, Pickar JH, et al. Coronary heart disease and menopause management: the swinging pendulum of HRT. Atherosclerosis. 2009;207(2):336–340. Available from: https://pubmed.ncbi.nlm.nih.gov/19560146/ doi: 10.1016/j.atherosclerosis.2009.05.033.
- Hsia J, Langer RD, Manson JAE, et al. Conjugated equine estrogens and coronary heart disease: the Women’s Health Initiative. Arch Intern Med. 2006;166(3):357–365. Available from: https://pubmed.ncbi.nlm.nih.gov/16476878/
- Poggio F, Del Mastro L, Bruzzone M, et al. Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis. Breast Cancer Res Treat. 2022;191(2):269–275. Available from: https://pubmed.ncbi.nlm.nih.gov/34731351/ doi: 10.1007/s10549-021-06436-9.
- Treweek S, Bevan S, Bower P, et al. Trial forge guidance 1: what is a study within a trial (SWAT)? Trials. 2018;19(1):1–5. Available from: doi: 10.1186/s13063-018-2535-5.
- Donovan JL, Jepson M, Rooshenas L, et al. Development of a new adapted QuinteT Recruitment Intervention (QRI-Two) for rapid application to RCTs underway with enrolment shortfalls—to identify previously hidden barriers and improve recruitment. Trials. 2022;23(1):258. Available from: doi: 10.1186/s13063-022-06187-y.
- Prinsen CAC, Vohra S, Rose MR, et al. How to select outcome measurement instruments for outcomes included in a “Core Outcome Set” – a practical guideline. Trials. 2016;17(1):449. Available from: doi: 10.1186/s13063-016-1555-2.
- Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288(1):49–57. Available from: https://pubmed.ncbi.nlm.nih.gov/12090862/ doi: 10.1001/jama.288.1.49.
- Gabes M, Knüttel H, Stute P, et al. Measurement properties of patient-reported outcome measures (PROMs) for women with genitourinary syndrome of menopause: a systematic review. Menopause. 2019;26(11):1342–1353. Available from: https://journals.lww.com/menopausejournal/Fulltext/2019/11000/Measurement_properties_of_patient_reported_outcome.18.aspx
- Utian WH, Woods NF. Impact of hormone therapy on quality of life after menopause. Menopause. 2013;20(10):1098–1105. Available from: https://journals.lww.com/menopausejournal/Fulltext/2013/10000/Impact_of_hormone_therapy_on_quality_of_life_after.19.aspx doi: 10.1097/GME.0b013e318298debe.
- Lensen S, Archer D, Bell RJ, et al. A core outcome set for vasomotor symptoms associated with menopause: the COMMA (Core Outcomes in Menopause) global initiative. Menopause. 2021;28(8):852–858. Available from: https://journals.lww.com/menopausejournal/Fulltext/2021/08000/A_core_outcome_set_for_vasomotor_symptoms.4.aspx doi: 10.1097/GME.0000000000001787.
- Khan K. The CROWN Initiative: journal editors invite researchers to develop core outcomes in women’s health. BJOG. 2014;17(5):520–521. Available from: doi: 10.3109/13697137.2014.930570.
- Chien PFW, Khan KS. Systematic review reporting – writing concisely and precisely. Pak J Med Sci. 2023;39(2):317–322.
- Godolphin PJ, White IR, Tierney JF, et al. Estimating interactions and subgroup-specific treatment effects in meta-analysis without aggregation bias: a within-trial framework. Res Synth Methods. 2022;14(1):68–78. doi: 10.1002/jrsm.1590.
- van Walraven C. Individual patient meta-analysis-rewards and challenges. J Clin Epidemiol. 2010;63(3):235–237. Available from: http://www.jclinepi.com/article/S0895435609001103/fulltext
- Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394(10204):1159–1168.
- Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases. BMJ. 2020;371:m3873. Available from: https://www.bmj.com/content/371/bmj.m3873 doi: 10.1136/bmj.m3873.
- Tierney JF, Fisher DJ, Vale CL, et al. A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials. PLoS Med. 2021;18(5):e1003629. Available from: doi: 10.1371/journal.pmed.1003629.
- Cintron D, Lipford M, Larrea-Mantilla L, et al. Efficacy of menopausal hormone therapy on sleep quality: systematic review and meta-analysis. Endocrine. 2017;55(3):702–711. Available from: doi: 10.1007/s12020-016-1072-9.
- Hamoda H, Morris E, Marshall M, et al. BMS, RCOG, RCGP, FSRH, FOM and FPH position statement in response to the BMA report ‘Challenging the culture on menopause for doctors’ – August 2020. Post Reprod Health. 2021;27(2):123–125.
- Department of Health and Social Care. Women’s Health Strategy for England. 2022.
- Russell J, Greenhalgh T, Taylor M. Patient and public involvement in NIHR research 2006–2019: policy intentions, progress and themes. 2019. [cited 2020 Apr 6]. Available from: https://oxfordbrc.nihr.ac.uk/wp-content/uploads/2019/05/NIHR-and-PPI-report-Feb_2019.pdf.
- Graham L, Illingworth BJG, Showell M, et al. Research priority setting in women’s health: a systematic review. BJOG. 2020;127(6):694–700. Available from: doi: 10.1111/1471-0528.16150.
- Moss N, Daru J, Lanz D, et al. Involving pregnant women, mothers and members of the public to improve the quality of women’s health research. BJOG. 2017;124(3):362–365. Available from: https://pubmed.ncbi.nlm.nih.gov/27862921/ doi: 10.1111/1471-0528.14419.
- Bagley HJ, Short H, Harman NL, et al. A patient and public involvement (PPI) toolkit for meaningful and flexible involvement in clinical trials – a work in progress. Res Involv Engagem. 2016;2(1):15. Available from: doi: 10.1186/s40900-016-0029-8.